HCPCS Level II code J2820 denotes a 50 mcg injection of sargramostim (gm-csf), an injectable biologic used to stimulate white blood cell production. This code matters nationally because sargramostim is used in oncology and hematology care pathways where growth factor support affects treatment delivery, patient outcomes, and drug utilization costs across outpatient and hospital settings. The analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will find a concise overview of clinical context for J2820, typical sites of service, and the payer landscape. The publication outlines benchmark metrics and reimbursement considerations, recent policy updates affecting coverage and billing practice, and operational implications for infusion centers and physician offices. The summary highlights variations in coverage policies among the listed payers, coding and claim submission considerations specific to HCPCS Level II drug reporting, and areas where facility billing workflows intersect with payer authorization and payment policies. Data not available in the input is noted where applicable.